DYNAMICS OF CLINICAL AND PSYCHOPATHOLOGICAL CHARACTERISTICS IN PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

Authors:

Abstract:

In the study 252 patients with negative symptoms of schizophrenia were examined: 83 patients with a first psychotic episode, 88 patients with schizophrenia in a state of exacerbation, and 81 patients with schizophrenia in a state of remission. The study of the clinical-psychopathological structure of patients with negative symptoms in schizophrenia at different stages of the disease included the analysis of the distribution of patients according to the severity of forms, the type of course and manifestations of schizophrenia, the duration and progression of the disease, the number of relapses, hospitalizations and the duration of episodes, and the presence of leading symptom complexes in the examined patients.

Keywords:

patients with schizophrenia negative symptoms clinical characteristics clinical and anamnestic analysis first psychotic episode schizophrenia in a state of exacerbation schizophrenia in a state of remission

References:

1. Kushnir YuA. Kliniko-anamnestychna kharakterystyka patsiyentiv z nehatyvnymy symptomamy pry shyzofreniyi. Ukrayinskyy visnyk psykhonevrolohiyi. 2023; 31(3(116)): 78-84. doi: 10.36927/2079-0325-V31-is3-2023-13 [in Ukrainian].
2. Al-Dujaili AH, Mousa RF, Al-Hakeim HK, Maes M. High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations with Interleukin-6, Symptom Domains, and Neurocognitive Impairments. Schizophr Bull. 2021; 47(2): 530-541. doi: 10.1093/schbul/sbaa136.
3. Bucci P, Galderisi S. Categorizing and assessing negative symptoms. Current opinion in psychiatry. 2017; 30(3): 201–208. doi: 10.1097/YCO.0000000000000322.
4. Dunayevich E, Chen CY, Marder SR, Rabinowitz J. Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: an analysis of the CATIE dataset. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2014; 24(10): 1615–1621. doi: 10.1016/j.euroneuro.2014.08.004.
5. Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2014; 24(5): 693–709. doi: /10.1016/j.euroneuro.2013.10.017.
6. Galderisi S, Färden A, Kaiser S. Dissecting negative symptoms of schizophrenia: History, assessment, pathophysiological mechanisms and treatment. Schizophr Res. 2017 Aug; 186:1-2. doi: 10.1016/j.schres.2016.04.046.
7. Havlovskyi OD. Main goals of psychological rehabilitation of military servicemen in the Poltava region under the present conditions. World of medicine and biology. 2020; 1(71): 36-39. doi: 10.26724/2079-8334-2020-1-71-36-39.
8. Institute of health Metrics and Evaluation (IHME). Global Health Data Exchange (GHDx). http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/27a7644e8ad28e739382d31e77589dd7 (25.09.21).
9. Jaeschke K. Global estimates of service coverage for severe mental disorders: findings from the WHO Mental Health Atlas 2017. Glob Ment Health. 2021; 8: e27.
10. Mantovani LM, Ferretjans R, Marçal IM, Oliveira AM, Guimarães FC & Salgado JV. Family burden in schizophrenia: the influence of age of onset and negative symptoms. Trends in psychiatry and psychotherapy. 2016; 38(2): 96–99. doi: 10.1590/2237-6089-2015-0082.
11. Sabe M, Sentissi О, Kaiser S. Meditation-based mind-body therapies for negative symptoms of schizophrenia: Systematic review of randomized controlled trials and meta-analysis, Schizophrenia Research. 2019; 212: 15-25. doi: 10.1016/j.schres.2019.07.030.

Publication:

«World of Medicine and Biology» Vol. 20 No. 89 (2024) , с. 121-126
УДК 616.895.8:615.86

DOI:

https://doi.org/10.26724/2079-8334-2024-3-89-121-126